Douglas Maxwell

2.1k total citations
50 papers, 1.4k citations indexed

About

Douglas Maxwell is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Pharmacology. According to data from OpenAlex, Douglas Maxwell has authored 50 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 10 papers in Cellular and Molecular Neuroscience and 9 papers in Pharmacology. Recurrent topics in Douglas Maxwell's work include Neuroscience and Neuropharmacology Research (7 papers), Antibiotics Pharmacokinetics and Efficacy (7 papers) and Phenothiazines and Benzothiazines Synthesis and Activities (6 papers). Douglas Maxwell is often cited by papers focused on Neuroscience and Neuropharmacology Research (7 papers), Antibiotics Pharmacokinetics and Efficacy (7 papers) and Phenothiazines and Benzothiazines Synthesis and Activities (6 papers). Douglas Maxwell collaborates with scholars based in United States, United Kingdom and Canada. Douglas Maxwell's co-authors include A. Loveless, Friedrich C. Luft, Rebecca Sloan, Lee A. Hebert, Wendy E. Hoy, Cheryl L. Kunis, Lawrence G. Hunsicker, Daniel Cattran, Marc A. Pohl and Gerald B. Appel and has published in prestigious journals such as Nature, New England Journal of Medicine and Diabetes Care.

In The Last Decade

Douglas Maxwell

47 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Douglas Maxwell United States 18 350 265 253 229 195 50 1.4k
John T. Sullivan United States 24 163 0.5× 391 1.5× 531 2.1× 295 1.3× 113 0.6× 52 1.8k
Bernhardt Sachs Germany 28 119 0.3× 367 1.4× 322 1.3× 572 2.5× 134 0.7× 126 2.3k
Charles A. Dinarello United States 15 102 0.3× 466 1.8× 141 0.6× 84 0.4× 147 0.8× 16 1.9k
Daniel Spratt United States 25 246 0.7× 453 1.7× 61 0.2× 72 0.3× 173 0.9× 50 2.2k
G. E. Mawer United Kingdom 22 92 0.3× 223 0.8× 166 0.7× 206 0.9× 50 0.3× 50 1.9k
Dawn McGuire United States 21 166 0.5× 391 1.5× 238 0.9× 197 0.9× 47 0.2× 37 1.9k
Jasper Stevens Netherlands 19 74 0.2× 323 1.2× 235 0.9× 160 0.7× 112 0.6× 97 1.8k
Olivier Boulat Switzerland 20 96 0.3× 325 1.2× 151 0.6× 55 0.2× 153 0.8× 50 1.6k
Peggy R. Borum United States 28 131 0.4× 760 2.9× 128 0.5× 61 0.3× 172 0.9× 78 2.6k
William J. Flanigan United States 16 170 0.5× 299 1.1× 87 0.3× 51 0.2× 169 0.9× 33 912

Countries citing papers authored by Douglas Maxwell

Since Specialization
Citations

This map shows the geographic impact of Douglas Maxwell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas Maxwell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas Maxwell more than expected).

Fields of papers citing papers by Douglas Maxwell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas Maxwell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas Maxwell. The network helps show where Douglas Maxwell may publish in the future.

Co-authorship network of co-authors of Douglas Maxwell

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas Maxwell. A scholar is included among the top collaborators of Douglas Maxwell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas Maxwell. Douglas Maxwell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
2.
Abou‐Saleh, Mohammed T., Paul Davis, Philip Rice, et al.. (2008). The effectiveness of behavioural interventions in the primary prevention of Hepatitis C amongst injecting drug users: a randomised controlled trial and lessons learned. Harm Reduction Journal. 5(1). 25–25. 33 indexed citations
3.
Kang, Jin-Yong, et al.. (2007). Gastrointestinal Symptoms in Patients With End-Stage Renal Disease Undergoing Treatment by Hemodialysis or Peritoneal Dialysis. The American Journal of Gastroenterology. 102(9). 1990–1997. 96 indexed citations
4.
Cattran, Daniel, Gerald B. Appel, Lee A. Hebert, et al.. (2001). Cyclosporine in patients with steroid-resistant membranous nephropathy: A randomized trial. Kidney International. 59(4). 1484–1490. 249 indexed citations
5.
Maxwell, Douglas, B. Atkinson, Bernd W. Spur, M H Lessof, & TL Lee. (1990). Skin responses to intradermal histamine and leukotrienes C4, D4, and E4 in patients with chronic idiopathic urticaria and in normal subjects. Journal of Allergy and Clinical Immunology. 86(5). 759–765. 49 indexed citations
6.
Vinicor, Frank, Alan M. Golichowski, Ronald S. Filo, Edwin J. Smith, & Douglas Maxwell. (1984). Pregnancy Following Renal Transplantation in a Patient with Insulin-dependent Diabetes Mellitus. Diabetes Care. 7(3). 280–284. 8 indexed citations
7.
Maxwell, Douglas, et al.. (1984). Primary glomerulonephritis complicating diabetic nephropathy: report of seven cases and review of the literature. Human Pathology. 15(10). 921–927. 26 indexed citations
8.
Aronoff, George R., Rebecca Sloan, Friedrich C. Luft, et al.. (1980). Mezlocillin pharmacokinetics in renal impairment. Clinical Pharmacology & Therapeutics. 28(4). 523–528. 5 indexed citations
9.
Bloch, R, Friedrich C. Luft, Laura I. Rankin, et al.. (1979). Protection from Gentamicin Nephrotoxicity by Cephalothin and Carbenicillin. Antimicrobial Agents and Chemotherapy. 15(1). 46–49. 28 indexed citations
10.
Luft, Friedrich C., R Bloch, Rebecca Sloan, et al.. (1978). Comparative Nephrotoxicity of Aminoglycoside Antibiotics in Rats. The Journal of Infectious Diseases. 138(4). 541–545. 117 indexed citations
11.
Wheat, L. Joseph, et al.. (1978). Immunofluorescent Localization of Staphylococcos aureus Antigen in Acute Bacterial Endocarditis Nephritis. American Journal of Clinical Pathology. 70(5). 832–835. 1 indexed citations
12.
Luft, Friedrich C., et al.. (1978). Pharmacokinetics of Netilmicin in Patients with Renal Impairment and in Patients on Dialysis. Antimicrobial Agents and Chemotherapy. 14(3). 403–407. 23 indexed citations
13.
McMurray, Stephen D., et al.. (1976). Acute tubular necrosis, a multifactorial analysis of variables.. PubMed. 6. 110–4. 2 indexed citations
14.
Rutter, Karoline & Douglas Maxwell. (1976). Diseases of the alimentary system. Constipation and laxative abuse.. BMJ. 2(6042). 997–1000. 6 indexed citations
15.
Maxwell, Douglas & W. Michael Asher. (1974). Ultrasound localization of the kidneys for closed renal biopsy. Journal of Clinical Ultrasound. 2(4). 279–280. 14 indexed citations
16.
Lunt, E., et al.. (1974). New inhibitor of reagin-mediated anaphylaxis. Nature. 251(5476). 650–652. 32 indexed citations
17.
Jordan, Roy, et al.. (1974). A COMPARISON OF THE EXPERIMENTAL ANTI‐ARRHYTHMIC PROPERTIES OF ACEBUTOLOL: (M & B 17,803), PROPRANOLOL AND PRACTOLOL. British Journal of Pharmacology. 50(3). 323–333. 24 indexed citations
18.
Maxwell, Douglas, et al.. (1972). A comparison of the pharmacological and biochemical properties of substrate‐selective monoamine oxidase inhibitors. British Journal of Pharmacology. 45(3). 490–503. 78 indexed citations
19.
Maxwell, Douglas, et al.. (1969). Bronchodilator Activity of an Aerosol of Prostaglandin E1 in Experimental Animals. Nature. 224(5214). 78–80. 34 indexed citations
20.
Maxwell, Douglas, et al.. (1968). Effect of phenothiazine derivatives on decerebrate rigidity. Naunyn-Schmiedeberg s Archives of Pharmacology. 259(2). 214–215. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026